An observational study in Acute Kidney Injury Due to Sepsis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Cairo University · Observational
Introduction: Acute kidney injury (AKI) occurs up to 50% of patients admitted to intensive care unit. Plasma Endostatin, released from basement membrane of Bowman's capsule, rises early during AKI.
Aim of Work: To investigate the role of the plasma endostatin in the outcome prediction (renal recovery, ICU stay, mortality) of acute kidney injury in patients with sepsis.
Methods: a prospective, observational single center study on 40 patients with Sepsis at the Critical Care Department, Cairo University hospitals between March 2019 and November 2019. Serum plasma endostatin was measured at the day of admission \& every 48hrs (3 samples). APACHE II, SOFA scores were calculated. Forced diuresis was used if indicated.
The study was conducted on 40 patients with sepsis who admitted in the Critical Care department of Cairo University.
The sepsis is identified according to surviving sepsis campaign guidelines with use of SOFA score to establish the diagnosis.
The patients divided into 2 groups the first group included 25 patients who developed AKI as defined by KDIGO guidelines and the other group included 15 patients as a control group.
The Plasma Endostatin level is sampled in the first 24 hours of diagnosis of AKI, the estimation of plasma Endostatin level done by ELISA technique.
The results were presented in form of: descriptive, analytical and comparative data between the groups of study.
It was found that the patients with higher levels of plasma endostatin had a higher incidence of recovery from AKI and higher incidence of 28 days survival, while the patients with lower levels of plasma Endostatin below the determined Cut-off value have increased incidence of RRT .
Also that the patients with higher levels of plasma Endostatin levels were less labile to mechanical ventilation and had a higher incidence of weaning of vasopressors in comparison of the other group of lower levels of plasma Endostatin.
Plasma Endostatin levels have no difference between the AKI group and sepsis group which may need further investigations to determine its role in sepsis.
so that, the plasma Endostatin can be used as a marker of recovery from AKI.
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's enrollment of 40 is below the median of 160 across 931 observational studies indexed under Sepsis.
Browse Sepsis studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Age: 18- 80 years .
The patients will be followed for development of acute kidney injury (AKI) defined according to criteria established by Kidney Disease Improving Global Outcome guidelines (KDIGO) 20129 which includes any of the following criteria:
Exclusion Criteria:
Patients admitted with the diagnosis of sepsis associated with elevation of renal function tests
Diagnostic Test: measuring plasma Endostatin level
Patients admitted with the diagnosis of sepsis with no elevation of renal function tests
Diagnostic Test: measuring plasma Endostatin level
measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
Renal outcme
Number of participants who have recovered renal functions \& those who needed Renal replacement therapy
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University